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Abstract
In the last 20 years, the prognosis of cystic fibrosis (CF) has slightly increased and
nowadays more than 50% of CF patients are adults. An obvious consequence of this
deep change is the increasing question about fertility in both males and females.
Almost 97% of male CF patients are infertile, having significant anatomical abnor‐
malities of the reproductive tract, in most cases a congenital bilateral absence of the
vas deferens (CBAVD); even if anatomical defect plays an important role, cystic
fibrosis transmembrane conductance regulator (CFTR) is directly involved in many
aspects of male reproduction, with well-known consequences in spermatozoa
capacitation and bicarbonate secretion.
Actually, male CF patients can become parents with assisted fertilization techniques:
intracytoplasmic sperm injection (ICSI), currently the most used fertilization
treatment worldwide, has dramatically improved the assisted reproduction outcomes
for men with obstructive azoospermia.
Most CF women have a normal reproductive tract and may be able to conceive
spontaneously, but multifactorial fertility problems can affect them also: the main
cause could be the difficult transport of sperm through the female reproductive tract,
secondary to thick secretions, but also lung function and nutritional status at the time
of conception significantly influence their fertility.
Keywords: Cystic fibrosis, CFTR, Congenital bilateral absence of the vas deferens,
Fertility, In vitro fertilization, Pregnancy
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1. Introduction
As the life expectancy of cystic fibrosis (CF) patients continues to increase, and more patients
become adults with a chronic disease, researching the impact of this disorder on male and
female infertility has become increasingly important.
Although most men with CF have significant anatomical abnormalities of the reproductive
tract causing infertility, most women with CF have anatomically normal reproductive tracts
and up to half of them may be able to conceive spontaneously.
Assisted reproductive technologies can help both infertile male and female patients with CF
in achieving successful parenthood. In addition, for women more health characteristics
including baseline pulmonary function have to be evaluated as predictors of health and
pregnancy outcomes.
2. Fertility in men with cystic fibrosis
CF is a systemic illness that affects multiple organ systems, including lungs, endocrine and
epithelial tissues, gastrointestinal system, pancreas, and reproductive tract. Because of the
dramatic improvement made in prognosis in CF population in the last two decades, reproduc‐
tive function has become one of the new red flags in the management of CF adult patients.
Infertility in CF males has been extensively studied and found in most cases to be secondary to
atrophy or malformation of the vas deferens, leading to an obstructive azoospermia (Figure 1).
Figure 1. Spermiogram performed in our 34-year-old patient affected by CF documents azoospermia
2.1. Pathogenesis
Cystic fibrosis transmembrane conductance regulator (CFTR) is a gene located on chromosome
7 (7q31.2), encoding for a protein located in the apical membranes of epithelial cells; it was
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identified in 1989 and its role in the pathogenesis of CF is now well known. CF is a disease
characterized by a defect in electrolyte and fluid transport in exocrine tissues; it could present
several different clinical manifestations, including chronic lung disease, pancreas insufficien‐
cy, and infertility [1].
In literature, it is reported that almost 97% of male CF patients are infertile [2]: this infertility
is primarily secondary to an obstructive azoospermia. The defective CFTR ion channel function
causes an early obstruction of male genital tract, due to the dehydrated secretions: this
mechanism drives to deep structural changes in reproductive tract, causing in most cases a
congenital bilateral absence of the vas deferens (CBAVD). In early studies on CF adult patients
with azoospermia, CBAVD was reported in all the population studied. At the light of these
findings, Holscalaw et al. [3] speculated a unique genetic cause of CF and CBAVD. Usually,
the proximal part of epididymis is present and this allows the sperm collection in CF patients
to obtain spermatozoa.
Obstructive dysfunction is not the only cause of infertility in males with CF: further studies
demonstrated that CFTR may also play a critical role in spermatogenesis and sperm maturation
[4]; an increased CFTR mutation frequency in a population of men with reduced sperm quality
is also reported [5]. Histological examination of CF testicular biopsies shows a wide range of
spermatogenesis abnormalities, including a decreased count of mature spermatids and
maturation arrest. These findings could be the expressions of CFTR abnormalities in seminif‐
erous tubules or spermatozoa.
CFTR plays a role in many aspects of male reproduction, with well-known consequences in
CBAVD and CF. It has not only ion channel functions but also it is a versatile signaling molecule
and interacts with more than 180 other proteins. CFTR is expressed throughout the whole
genital tract [6], but we do not know yet what is CFTR’s role in the male accessory glands other
than the epididymis.
A significant role in sperm function was also suggested by the involvement of CFTR in uterine
HCO3– secretion and its effect on the fertilizing capacity of sperm [7]. CFTR is present in human
sperm and it is involved in both sperm motility and capacitation phases. CF mice sperm has
reduced sperm motility and capacitation with reduced fertility rate in vitro and in vivo [8]:
these findings suggest a significant role of CFTR in sperm functions also.
2.2. CBAVD
CBAVD is a congenital condition in which vas deferens fails to develop properly, causing male
infertility because of the total obstruction of reproductive tract. CBAVD accounts for approx‐
imately 1–2% of all infertility in males and is the result of genetic abnormalities [9]. More than
half of the men with CBAVD (62–80%) carry a CFTR mutation and this condition is considered
to be one of the most common CFTR-related diseases. Anatomical abnormalities include
bilateral or unilateral absence of the vas deferens and seminal vesicles anomalies.
Subjects with CBAVD usually have no clinical symptoms of CF, but the finding of subclinical
CF features is not uncommon (mild chloride elevation at sweat test, chronic sinusitis, nasal
polyps) and actually many experts consider CBAVD as a mild CF form [9].
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2.3. Other genital abnormalities
Genital abnormalities may develop early in CF, but in children these are less common than
described in adults. In 2002, Blau et al. [10] described genital abnormalities in male children
with CF, performing pelvic and scrotal ultrasonography in 12 CF boys aged 2–12 years. They
found seminal vesicles hypoplasia, testicular microlithiasis, and abnormalities of the epididy‐
mal head, such as cysts, hypo-, or hyper-echogenicity. These findings are more frequent in
pancreatic-insufficient than in pancreatic-sufficient CF patients. The reported experience
represents a very small population of CF children, and larger longitudinal studies will be
necessary to better define the onset and progression of urogenital abnormalities in CF males.
In CF adults, testes are usually symmetric and have a normal echogenicity, but mild inhomo‐
geneity or striated appearance can be documented with ultrasounds. Focal inhomogeneities
seem to be rare, as testicular nodules. Didymus cysts, epididymal cysts (also multiple) with
sediments and/or calcifications are common. Usually, vas deferens is absent, but a structure
attributable to spermatic cord could be revealed bilaterally or unilaterally in some cases,
usually with a significant stenosis.
Several features can influence the anatomical genital phenotype in these patients (as genotype,
clinical features, age), and further studies will be crucial to find risk factors and significant
correlation for these abnormalities in CF.
2.4. Fertility management in men with CF
Over the last 20 years, the relevant improvement in survival of CF patients and the concomitant
development of new assisted conception methods have significantly increased the opportu‐
nities for these patients to become parents. It is therefore very important to start an early and
effective management of fertility issues in males with CF.
The clinical management of reproductive issues in males affected by CF has to begin during
puberty with periodic evaluation of testicular volume/consistency and all the other virilization
signs, indicating a congruous testosterone production. Hormonal levels (as LH, FSH, and
testosterone serum concentration) are usually normal in male CF, indicating a regular
spermatogenesis in most cases. It could be also useful as a deeper examination to detect the
presence of vas deferens (usually palpable in the upper portion of scrotum), but the definitive
diagnosis of CBAVD can be made with radiological exams.
There is not a considerable literature about the morphological study of the scrotum in adult
CF patients, but trans-rectal ultrasounds could be considered a good instrument to evaluate
abnormalities in shape, volume, and structure of testes, epididymis, and spermatic cord.
Also scrotal ultrasound with high-definition instruments is non-invasive and executable
without any discomfort for the patient and could be useful in order to analyze the extra pelvic
portion of the vas deferens (from the groin to the testicle) and all the scrotal structures.
The diagnosis of azoospermia could be simply supported and confirmed by semen analysis.
In case of seminal vesicles abnormalities, semen analysis will also show an acid pH, due to
lack of fructose concentrations in sperm, and often the volume of ejaculate is low: in these
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cases, the sperm is produced by the prostate, with no contribute from vesicles. Typically,
men with the absence of the vas deferens have low-volume (often less than 0.5 ml) and
acidic semen [11].
2.5. Assisted reproduction in men with CF
2.5.1. Counseling
CF men and their partners, who want to start assisted reproduction treatments, need an
adequate genetic, medical, and psychological counseling. Genetic tests have to be performed
in the patient (if not already done) and in the partner, in order to define the risk of generating
an affected child. In case of incomplete genetic assessment or high risk of CF recurrence,
prenatal or pre-implantation genetic diagnosis could also be recommended; it is important to
consider ethic and legislative issues, because in some countries pre-implantation genetic tests
are not allowed. All these procedures have relevant psychological, ethical, and sanitary costs,
so alternative measures (as adoption or use of sperm donor) could be considered.
Another important issue is the prognosis of the potential father affected by CF. This delicate
aspect asks the intervention of CF-clinician and psychologist, together with an experienced
fertility specialist.
2.5.2. Sperm collection
Sperm retrieval is a procedure used to obtain sperm for fertility purposes. In general, it is
necessary in case of azoospermia or if men are unable to ejaculate. In almost all cases, sperm
retrieval must be utilized in combination with in vitro fertilization (IVF) and intracytoplasmic
sperm injection (ICSI) for reasonable pregnancy rates to be obtained [12].
The sperm collection could be performed by aspiration from epididymis or directly from the
testis. In CF the proximal part of the epididymis is usually present, so the procedure is usually
quietly simple. The techniques of collection include:
• Percutaneous epididymal sperm aspiration (PESA) from the caput of the epididymis,
usually simple to localize and good reservoir of sperm; aspiration is performed with fine
needle after local anesthetization and is usually fast and well tolerated by the patient
• Microsurgical epididymal sperm aspiration (MESA)
• Percutaneous testicular aspiration (TESA) performed with local anesthetization (Figure 2)
as for PESA
• Testicular surgical biopsy (Figure 3)
• Testicular sperm extraction (TESE), an in vivo microdissection of testicular tubules finalized
to the identification of normal tubules (Figure 4), suitable for an effective sperm collection
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Figure 2. Percutaneous testicular aspiration (TESA) performed with local anesthetization
Figure 3. Percutaneous testicular biopsy
Cryopreservation of sperm is possible and represents a good chance for future use, but usually
repeated epididymal aspiration is required. These procedures are usually performed on the
same day of the partner’s oocytes collection (Figure 5) to assure high counts of motile sperm
in the time of fecundation.
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Figure 5. Oocytes culture
2.5.3. Assisted reproduction treatments
The first experience of in vitro fertilization with sperm obtained by epididymal aspiration was
in 1985 [13]; in the next years, several experiences also in CBAVD patients have been reported
[14]. In that period, the fertilization rates were low (less than 20%), with very poor birth rates.
A dramatic increase in assisted reproduction outcomes for men with obstructive azoospermia
has been represented by ICSI, introduced first in the 1990s. The first large experience with ICSI
in the United States was published by Sherins et al. in 1995 [15]. This technique is generally
performed following an in vitro fertilization procedure to extract one to several oocytes from
a woman. The procedure is done under a microscope, using multiple micromanipulation
devices, in order to allow the direct injection of a single sperm in a human oocyte.
Figure 4. Microsurgical identification of tubules with spermatogenesis (TESE technique)
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This technique is currently the most used fertilization treatment worldwide and it has deeply
increased the chances of successful fertilizations and pregnancies; ICSI technique allows to
have the same fertilization and pregnancy rates between CF males and men with no vas
deferens obstructive disease (Figure 6).
Figure 6. ICSI technique
3. Fertility in women with cystic fibrosis
Although most men with CF have significant anatomical abnormalities of the reproductive
tract, most CF women have an anatomically normal reproductive tract and may be able to
conceive spontaneously, but in literature it is reported that only slightly more than half of them
have spontaneous pregnancies. The fertility problems in CF female are multifactorial: the main
cause would be the difficult transport of sperm through the female reproductive tract,
secondary to thick secretions; but certainly also the underlying medical conditions (especially
lung function and nutritional status) have a major impact on fertility in these patients. The
improved health and longevity of CF women naturally leads to an increased number of CF
women who become or desire to become pregnant.
The first reported successful pregnancy in a CF woman was in 1960 [16], and in 1966 13
pregnancies in 10 different patients were reported [17]. These early reports were discouraging.
However, with aggressive management of infections and significant improvement in pulmo‐
nary and nutritional interventions, pregnancies today are well tolerated in CF, especially in
women with mild to moderate disease [18, 19]. The North American CF Registry reported in
2007 that 3–4% of CF women over 17 years old become pregnant each year [20].
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3.1. Pathogenesis
Despite CF has long been associated with female infertility, the underlying causes remain
unclear. Actually, we know that the majority of CF women have a normal fertility, but
ovulation disturbance may occur in patients with advanced disease [21], also with amenorrhea
in the most compromised subjects. Although most girls have normal menstrual cycles, there
is a higher incidence of missed or irregular periods and amenorrhea. This is more likely in
those with a reduced percentage of body fat and may occur in case of malnutrition or alimen‐
tary disorders.
Fertility problems may be related to lung disease severity, poor weight, and to an unsatisfying
control of CF-related diabetes [22]. Historically, the predictors of poor pregnancy outcome for
mother and/or fetus were a forced vital capacity (FVC) of less than 50% of the predicted value
and poor nutritional status. In the past, an FVC of less than 50% of the predicted value was an
absolute contraindication to pregnancy.
For several years, it has been postulated that the thickened cervical mucus present in CF
women reproductive tract could lead to fertility disturbance. Normally, when the egg is
released from the ovary, cervical and uterine mucus thins and allows easier passage of sperm
into the uterus and fertilization. Increased thickness of this mucus in women with CF may
theoretically act as a barrier to sperm penetration and could reduce fertility, but nowadays the
majority of women with CF can become pregnant without any difficulty.
In 2008, Hodges et al. [23] studied the mouse model of CF, indicating that in CF mice the major
cause of decreased fertility is the impaired sperm transport within female reproductive tract.
In their experience, excess cervical mucus played a minor role, because instead of a physical
barrier, the decreased fertilization seemed to be due to an inadequate fluid production in
reproductive system, with a subsequent decrease in sperm number in the oviduct. CFTR could
play not only an important role in female reproductive tract fluid control but also in sperm
capacitation with its bicarbonate transport.
3.2. Impact of pregnancy on CF
The physiologic changes associated with pregnancy may contribute to increased morbidity
and mortality risks for the mother in CF women. Volumetric increase of abdomen with the
consequent upward displacement of diaphragm causes a decrease in functional residual
volume, and the concomitant increase in resting minute ventilation can lead to a relevant
breath disturbance. Also gas exchange has deep alterations in pregnant women, with an
increased alveolar–arterial oxygen gradient, especially in supine position [24].
In a recent study [25], it is reported that adjusting for the FEV1 percent predicted, weight,
height, and pulmonary exacerbation rate per year, pregnancy is not associated with an
increased risk of death. Pregnancy did not appear to be harmful even in a subset of women
with diabetes mellitus or with FEV1 less than 40% of predicted. Important predictors of
pregnancy outcome for the fetus are the severity of maternal pulmonary impairment and
nutritional status; in women with advanced lung disease, preterm delivery is very common.
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McMullen et al. [26] in 2006 characterized health outcomes in CF pregnant women, comparing
them with a group of never-pregnant CF population: this large observational study showed a
nonsignificant difference in terms of FEV1 decline between the two groups (6.8% in pregnant
group and 4.7% in never-pregnant, P=0.61). Respiratory exacerbations and hospitalizations
were increased during pregnancy, as well as the number of outpatient visits and administered
therapies.
The risk for congenital anomalies in the fetus is not increased in CF gravidas and breastfeeding
is possible without complications.
3.3. Risk factors
The pregravid pulmonary function is clearly the greatest outcome predictor in CF women, but
there are multiple clinical prognostic markers to consider. Women with poor nutritional status,
pulmonary hypertension, and relevant decrease in pulmonary function during the first 3
months of gestation have to be informed about the high risk of maternal mortality and should
consider therapeutic abortion [27].
3.3.1. Lung function
FEV1% predicted, PO2, and PCO2 are important predictors of pregnancy outcomes. In 1995,
Edenborough et al. [28] reported that a pregravid FEV1 <60% caused greater pulmonary
function decrease, a higher frequency of preterm infants, and also a higher mortality. However,
successful pregnancies have been reported also in CF patients with compromised lung
function (FEV1 < 50% of that predicted), and most patients seem to return to baseline pulmo‐
nary status after pregnancy.
The only absolute contraindication to pregnancy in CF is represented by pulmonary hyper‐
tension, which is correlated with higher rates of mortality in pregnancy. An echocardiogram
performed before pregnancy can be useful to individuate underlying pulmonary hypertension
and cor pulmonale, in order to advise the patient about the high mortality risk in case of
pregnancy [24].
3.3.2. Pancreatic insufficiency and diabetes mellitus
In old literature, pancreatic insufficiency was considered as a major risk factor in pregnancy
outcomes. Actually, with the modern pancreatic enzymes supplementations, it is a nonsigni‐
ficant issue in CF pregnancies.
CF women planning pregnancy have to be tested for glucose intolerance before conception
and the test has to be repeated at 20 weeks of gestational age. Insulin therapy is indicated in
case of abnormalities in blood glucose monitoring.
3.3.3. Nutritional status
Clinician should advise to reach a pregravid weight before conception up to 90% of the ideal
body weight. Poor nutritional status is without any doubt one of the most relevant risk factor
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for pregnancy outcomes in CF, and a severe malnutrition (BMI <18 kg/m2) is a relative
contraindication to pregnancy. A weight gain of 11–12 kg during pregnancy is recommended
[29]; poor outcome is particularly associated with a maternal gain less than 4.5 Kg. A high
caloric intake should be maintained and a poor weight gain is an indication for aggressive
nutritional intervention (dietary supplementation, nasogastric, or gastrostomy feeding).
3.3.4. Microbiological issues
Burkholderia cepacia complex has been considered for several years a relative contraindication
for pregnancy in CF, because this infection seemed to be related with a higher maternal
mortality [30]. B. cepacia (particularly B. cenocepacia and B. multivorans) is also considered
related to preterm delivery, weight loss, and rapid pulmonary function decline [31], but further
studies are needed to better define its role in CF pregnancies.
3.3.5. Pulmonary transplantation
Limited cases of pregnancy after lung transplantation have been reported; most experience
comes from renal transplantation. Compared to other solid organ transplants, lung recipients
experience more frequent rejections during pregnancy and also a higher rate of graft loss
postpartum [32]. Graft dysfunction is unpredictable and may occur anytime during pregnancy,
leading to progressive decline and also eventual death after delivery. However, further studies
are necessary to determine long-term maternal survival.
Prematurity and neonatal complications in these pregnancies are very high (56% and 33%,
respectively), but no long-term consequences on children are reported [33].
3.4. Management of pregnancy in CF women
The management of pregnancy in CF requests necessarily a multidisciplinary approach. Most
of the literature on pregnancy in CF is constituted by case reports and a few national centre
based reviews. Unfortunately, at the moment, we have no available trials about any aspect of
pregnancy management in CF. In 2008, Edenborough et al. [34] published the guidelines for
the management of pregnancy in women with CF, based on the review of the literature and
experience of pediatricians, adult and transplant physicians, nurses, physiotherapists,
dietitians, pharmacists and psychologists experienced in CF, and also anesthetists and
obstetricians with experience of CF pregnancy.
3.4.1. Counselling
Counselling consists in helping the CF patient planning pregnancy and her partner to explain
the risks of their decision, such as medical implications, treatment options, and also the impact
of a toddler on the everyday life of a CF woman.
Genetic features, such as the risk of recurrence of the disease, have also to be discussed with
the couple. CF genotype, if not already known, have to be defined and the partner should also
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be tested before conception. Genetic counsellors should be involved in order to discuss these
delicate issues with the couple.
Genetic tests have a sensitivity <100% with detection rates from 70% to 95% of CFTR mutations.
If the partner has not been tested, given a CF carrier frequency of 1:25, the risk of an affected
infant is 1:50; while if the partner is a CF carrier, the risk is 1:2.
When the partner is a known carrier or if he has not been tested, clinicians should suggest to
perform prenatal genetic diagnosis to the couple, with the analysis of chorionic villus sample
(CVS) within the first trimester of gestation. This procedure includes technical risks that should
be discussed with the couple.
Psychological counselling is also an important part of the counselling activities: CF team
should provide information about sexual health and reproduction to all of their patients,
particularly teenage girls. Psychologists and clinicians play an important role also in psycho‐
logical counselling for CF women who want to become pregnant, even if women with
advanced disease with a very strong wish to have a child may proceed whatever the advices.
3.4.2. Medications during pregnancy
Most drugs have not been tested on pregnant women. Relevant issues about their use in
pregnancy are timing of exposure (periconception, first, second, third trimester, or perinatally),
systemic availability of the drug, and its ability to cross the placenta. Side effects can consist
in teratogenesis, growth retardation, death, renal insufficiency, neurological disorders,
stillbirth, etc.
Many pregnancies are unplanned and drugs could have been taken at the time of conception
and continued in the first weeks of pregnancy, and many women with serious illnesses
required treatment to be continued. Even if nowadays there is experience to guide prescribing
in pregnancy, the principle remains to avoid drug use where possible, except when the risk of
the drug is outweighed by the risk of the condition being treated.
The Swedish FASS information catalog provides information on the risks of drugs to the fetus
during pregnancy and to the infant during lactation. Each drug is classified to one category of
safety:
1. Drugs that have been used widely during pregnancy and are assumed safe for the fetus
2. Drugs not known to cause harm to the human fetus but with insufficient experience to
consider them safe. This category can be subdivided into
3. drugs that have been demonstrated to cause no harm in animal studies
4. drugs with insufficient animal data
5. drugs that have been demonstrated to harm the fetus only in animal studies
6. Drugs that could theoretically cause harm to the fetus by their pharmacological actions
7. Drugs known or believed to cause harm to the fetus
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Patient’s therapy should be reviewed during the discussion of a potential pregnancy, even if
most of the routine CF medications are safe and could be continued. Contraindicated drugs
have to be discontinued. β-lactams are safe in pregnancy and aminoglycosides at conventional
doses have not showed toxic results. Once-daily tobramicin has been tested in second and third
trimesters, showing safe results. Ciprofloxacin has been widely used during pregnancy with
no certain side effects, but its use is indicated only if vital for the mother.
3.4.3. Lung function and infections
CF women can become pregnant in all pulmonary disease stage, but the outcome for the
mother and the newborn is closely related to lung function (FEV1 predicted) and clinical
stability. Lung function should be optimized and chronic infections may be suppressed before
pregnancy: oral flucloxacillin could be administered in case of Staphylococcus aureus coloniza‐
tion; for Pseudomonas aeruginosa nebulized colistin or aminoglycoside treatment should be
employed.
When a pregnancy is unplanned, pregnancy is frequently connected to a worsening in lung
function: if necessary, one or more courses of IV antibiotic treatment could be administered in
the usual format also during pregnancy (β-lactam + aminoglycoside).
During the first trimester, most patients will feel breathless and the frequency of hospitaliza‐
tions could rise up: at each visit, physical examination, sputum cultures, weight and oxygen
saturation measurement, and pulmonary function test should be performed.
3.4.4. Physiotherapy
If the pregnancy is planned, preconceptional period could represent a good opportunity to
optimize the daily physiotherapy program. Inhalation therapies and techniques should also
be reviewed and optimized; the timing of these treatments in relation to airway clearance
therapy (ACT) is a relevant feature during pregnancy, especially in CF patients who produce
big volumes of sputum. ACT adherence and technique have to be adapted in pregnant women.
Advice on physical exercise and pelvic floor strength should be given as soon as possible.
The breathing pattern is affected by physiological and mechanical changes during pregnancy,
and in the last trimester these features can lead to increase in closing volume and determine
atelectasis. Physiotherapists should meet the pregnant patients weekly to optimize the
physiotherapy regimen, monitor lung function and sputum production in terms of colour and
quantity. Also maintaining exercise capacity should be useful during pregnancy and in last
trimester.
3.4.5. Nutrition
Dietetic counselling is crucial in preconceptional period, because maternal nutritional state is
one of the most important factors influencing outcomes for mother and infant. A low pre-
pregnancy BMI is strictly associated with reduced birth weight. Preconceptional assessment
is similar to non-CF population and should be performed by a CF specialist dietitian, who can
advise not only on increasing energy density of the diet but also oral supplements and invasive
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nutritional support (enteral tube feeding) can be purposed to the patient if nutritional status
is unsatisfactory. Vitamin supplementation with folic acid, vitamin A, and vitamin D are
recommended.
An overall weight gain of 12.5 Kg is considered normal and in CF it is recommended a weight
gain of at least 11 Kg. Also gastro-oesophageal reflux, heartburn, nausea, recurrent vomiting,
and constipation may occur more frequently in women with CF and required clinicians
monitoring.
3.4.6. Diabetes care
A pre-pregnancy diagnosis of CF-related diabetes and gestational diabetes are associated with
a poorer prognosis; in literature, it is reported that an unsatisfactory glycemic control in the
first trimester is associated with an increased risk of teratogenesis. During preconceptional
counselling an OGTT is recommended, if not already performed, and blood sugars have to be
monitored during lung exacerbations. Usually, OGTT is repeated at 20 weeks gestation and
glycaemia should be measured at every visit: if random values are high, another OGTT could
be repeated at 28 weeks.
Insulin is the recommended treatment for diabetes in CF also during pregnancy. A high calorie
intake should also be assessed in diabetic patients.
3.4.7. Termination of pregnancy
Guidelines about when to terminate pregnancy in a woman with advanced CF remain fluid.
The indications may be psychosocial (in order to prevent serious injury to the mental health
of the pregnant woman) or medical.
The only absolute contraindication to pregnancy is a pre-existing pulmonary hypertension
with cor pulmonale; also chronic hypoxia could be considered a contraindication to pregnancy.
There are no clear indications about the FEV1 cut-off to recommend pregnancy termination.
There are also some relative contraindications to pregnancy in CF women:
1. Poor nutritional status (BMI <18 kg/m2; <85% ideal body weight)
2. Uncontrolled CF-related diabetes
3. Burkholderia cepacia infection
4. Significant liver disease
3.4.8. Delivery
Most pregnancies in CF end in spontaneous vaginal delivery. Caesarean section is indicated
only in case of maternal or fetal sufferance, preferably with spinal anesthesia. In CF, a high
proportion (26–46%) of pregnancies end up with a spontaneous or therapeutic preterm
delivery, and the usual indication is represented by maternal conditions. Usually, failing lung
function and hypoxia occur in patients with a significant low pre-pregnant lung function;
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persisting hypoxia and onset of headache are in these cases severe signs and could request
oxygen support or non-invasive ventilation.
In peripartum, pain and anxiety can lead to hyperventilation and decrease in alveolar gas
exchanges; hypoxia, hypercarbia, and respiratory acidosis occur rapidly in patients with
compromised lung function. An adequate analgesia should be performed, because it reduces
pain, fear, and fatigue; oxygen support can be useful in case of desaturations.
4. Our experience
In our CF Center, we have 230 patients in regular follow-up and 153 of these are >18 years old.
In the last few years, fertility issues increased significantly in our population, surely because
of the significant improvement in prognosis and the easier access to the assisted reproduction
treatments.
During the last 20 years, 12 of our male patients recurred to in vitro fertilization with sperm
obtained by epididymal aspiration and in 6 cases had successful reproduction (with twin
pregnancy in 2 cases and in 1 case triplet pregnancy). All the newborns enjoyed good health
and no recurrence of CF has been detected (all the partners were tested for CFTR mutations
before the conception). In the other six cases in vitro fertilization was not successful and one
of these three patients decided to use heterologous fertilization by sperm donor, with a
subsequent successful pregnancy.
In the same period four of our female patients recurred to in vitro fertilization with two
successful pregnancies (in one case twin pregnancy). Also in these cases the newborns enjoyed
good health and no recurrence of CF has been detected (all the partners were tested for CFTR
mutations before the conception).
In our population 12 of our patients (10 women and 2 men) had spontaneous conceptions with
18 successful pregnancies. Also in these cases no recurrence of the disease has been detected,
even if in some cases the diagnosis of CF in these patients had been performed after the delivery
and in most cases the partners had not been tested for CFTR mutations before the conception.
Three of our female patients, after several attempts to become pregnant spontaneously,
decided and obtained to adopt a child.
Actually, no literature is available about scrotal imaging in males affected by CF. We decided
to realize an original study, performing scrotal ultrasound examination with high-definition
technique, to better evaluate abnormalities in shape, volume, and structure of the testes,
epididymis, and spermatic cord in a group of adult patients (>18 years) affected by CF.
Preliminary results seem to show an increased incidence of testicular and epididymal abnor‐
malities in comparison to the general population, but in most cases these seem to be secondary
to the obstruction of vas deferens [FigureS 7,8,9].
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Figure 7. US Figure of rete testis ectasia with structure inhomogeneities in a CF patient
Figure 8. US Figure of rete testis ectasia with structure inhomogeneities with a little epididymal cyst in a CF patient
Figure 9. US Figure of intradidymal cysts (one with corpuscular content) in a CF patient
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Nomenclature
CF = Cystic fibrosis
CFTR = Cystic fibrosis transmembrane conductance regulator
CBAVD = Congenital bilateral absence of the vas deferens
LH = Luteinizing hormone
FSH = Follicle stimulating hormone
US = ultrasounds
IVF = in vitro fertilization
ICSI = Intracytoplasmic sperm injection
PESA = Percutaneous epididymal sperm aspiration
MESA = Microsurgical epididymal sperm aspiration
TESA = Percutaneous testicular aspiration
TESE = Testicular sperm extraction
FVC = forced vital capacity
FEV1 = Forced expiratory volume in 1 second
PO2 = Partial pressure of oxygen
PCO2 = Partial pressure of carbon dioxide
BMI = Body mass index
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